Effect of Treatment Delay on Tumor Stage among Symptomatic Patients with Earlyonset Colorectal Cancer: a Retrospective Cohort Study

Yaya Sun,Guangqing Jiang,Zhaiyue Xu,Yihong Zhang,Yanxuan Ling,Xin Shi
DOI: https://doi.org/10.21203/rs.3.rs-2845522/v1
2023-01-01
Abstract:Abstract Background: The incidence of colorectal cancer (CRC) among adults younger than 50 years of age has continued to increase in many countries over the past two decades. Among younger patients with CRC, a lower awareness of symptoms may contribute to treatment delay, which perhaps leads to adverse consequence on tumor stage. Therefore, the purpose of this study was to determine whether delayed treatment influences the staging of CRC among symptomatic patients under the age of 50 years. Methods: In a retrospective cohort study, all pathologically diagnosed early-onset colorectal cancer patients (<50 years) were selected and a part of colorectal cancer patients aged 50 years and older were randomly selected by the proportion of 1:4 in Zhongda Hospital affiliated to Southeast University from March 1, 2014 to September 31, 2021. We compared clinical symptoms, pathological features, treatment delay and tumor stages between younger patients (n= 121) and older patients (n=443). Results: Patients with early-onset CRC had higher rates of dMMR (20.0% vs 10.9% in older patients, p=0.012), high-grade adenocarcinoma (17.3% vs 9.4% in older patients, p=0.021), and mucinous adenocarcinoma (11.6% vs 5.6% in older patients, p=0.023). The median treatment delay among CRC patients was slightly longer in the younger group than in the older group (80 days [IQR 32-167] vs 53 days [IQR 20-159], p=0.028), and treatment delay was mainly caused by patient's delay. However, the proportion of stage III and stage IV tumors in younger patients (52.9%) was similar to that in older patients (46.0%) (p=0.182). In multivariable analyses, age was not a factor contributing to treatment delay in patients with CRC. Among early-onset CRC patients, 57.8% of patients with treatment delay of less than 3 months had stage III and stage IV tumors, while the proportion of stage III and stage IV tumors in patients with treatment delay of more than 3 months was 47.4%. There was no significant difference between the two groups (p=0.251). Conclusions: In the retrospective analyses of patients with CRC in our center, we found that although treatment delay of patients with early-onset CRC was moderately longer than that of patients aged 50 years and older, age was not a factor leading to the delay in treatment. In addition, this level of delayed treatment didn't have a negative impact on tumor stage.
What problem does this paper attempt to address?